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Putting Theory into Practice: James Black,
Receptor Theory and the Development of the
Beta-Blockers at ICI, 1958–1978
VIVIANE QUIRKE*
Introduction
The concept of drug receptors has played a significant role in the biomedical sciences
and in pharmaceutical innovation in the second half of the twentieth century. Although the
concept dates back to the work of the German bacteriologist and immunologist Paul
Ehrlich and of the British physiologist John Newport Langley at the end of the nineteenth
and the beginning of the twentieth century, its acceptance was delayed because of con-
flicting ideas about drug action, and because of uncertainties and hesitations about the
concept itself.
1
As a consequence of such conflicts and hesitations, the concept remained highly
speculative, and its application was delayed. According to Andreas-Holger Maehle,
Cay-R€ u udiger Pr€ u ull and Robert Halliwell: ‘‘it was not until Raymond P. Ahlquist
(1914–1983) made his famous distinction, in 1948, between a- and b-adrenoceptors,
that receptor research began to provide a powerful basis for pharmaceutical innovation’’.
2
One of the key events in the establishment and acceptance of the concept of receptor was
the introduction in 1965 of propranolol as ‘‘the first clinically useful beta-receptor
blocker’’,
3 for which James (now Sir James) Black was awarded the Nobel Prize in 1988.
4
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1See J Parascandola, ‘Origins of receptor theory’,
Trends Pharmacol. Sci., 1980, 1: 189–92; idem, ‘The
development of receptor theory’, in M J Parnham and
J Bruinvels (eds),Discoveriesin pharmacology, vol. 3,
Pharmacological methods, receptors and
chemotherapy,Amsterdam,Elsevier,1986,pp.129–56.
On the development of the receptor concept by
Paul Ehrlich, see C-R Pr€ u ull, ‘Part of a scientific master
plan? Paul Ehrlich and the origins of his receptor
concept’, Med. Hist., 2003, 47: 332–56; on John
Langley’sroleintheelaborationofreceptortheory,see
A-H Maehle, ‘‘‘Receptive substances’’: John Newport
Langley (1852–1925) and his path to a receptor theory
of drug action’, Med. Hist., 2004, 48: 153–74.
2A-H Maehle, C-R Pr€ u ull and R F Halliwell,
‘The emergence of the drug receptor theory’, Nature
Reviews, Aug. 2002, 1: 637–41, on p. 641. See also
C-R Pr€ u ull, A-H Maehle, and R F Halliwell, ‘Drugs and
cells—pioneering the concept of receptors’,
Pharmacy in History, 2003, 45: 18–30.
3See the time line in Maehle, et al., op. cit.,
note 2 above, p. 638.
4On Black, see V P Gerskowitch, R A D Hull, and
N P Shankley, ‘The ‘‘pharmacological toolmaker’s’’
rational approach to drug design: an appreciation of
Sir James Black’, Trends Pharmacol. Sci., 1988, 9:
435–7. See also V Quirke, ‘Black, James Whyte’,
Encyclopedia of life sciences, 20 vols, London, Nature
Publications Group, 2002, vol. 3, pp. 300–1.
69Black himself has emphasized the link between Ahlquist’s theory of two receptors,
propranolol, and the investigations that followed the drug’s discovery:
Now there is no doubt that [Ahlquist’s] theory of two receptors had a powerful influence in
directing the studies of clinical investigators once suitable agents, such as propranolol, became
available. There is equally no doubt that my own work begun in 1958, to find a way of reducing
myocardial demand for oxygen in hearts whose oxygen supply was restricted by arterial disease,
would not have been started but for the existence of Ahlquist’s theory.
5
In fact, propranolol (also known under its trade name Inderal) replaced pronethalol
(Alderlin), which was the first clinically useful beta-blocker (see Table 1). Like propra-
nolol, pronethalol had been developed by Black at Alderley Park, Imperial Chemical
Industries’ (ICI) pharmaceutical research centre in Cheshire, south of Manchester.
6
However, unlike pronethalol, which was withdrawn from the market because it was
found to cause thymic tumours in mice, propranolol became a best-selling drug, used
for the treatment of a wide range of cardiovascular diseases, from angina pectoris to
hypertension, a success attributable to ICI’s research and development (R&D) and com-
mercial strategy as well as to Black’s inventiveness and skill. As such, propranolol was to
play an important part in the acceptance of the receptor concept in scientific circles, and in
the use of receptor theory as a tool for pharmaceutical innovation.
The main focus of this paper is on the development of receptor theory and its impact on
the R&D programme of the company which discovered the first clinically useful beta-
blockers:ICI’sPharmaceuticalDivision,whereitcametoplayanimportantpartinrational
drug design, an aspect largely overlooked by histories of receptor theory and of the beta-
blockers. Not only does this paper aim to fill an important gap in the historiography, but it
provides fresh insights on the roles of the individual scientist, James Black, who brought
Ahlquist’s dual receptor theory with him when he moved to Alderley Park, and the
industrial research team, who applied it, turning it into a new class of drugs.
As well as published sources, I have used the research reports of ICI, which—although
by no means exhaustive—are the principal archival resource currently accessible on the
subject. I have consulted these reports, written twice a year by the different project leaders
5J W Black, ‘Ahlquist and the development of
beta-adrenoceptor antagonists’, Postgrad. med. J.,
1976, 52, Suppl. 4: B I Hoffbrand, R G Shanks, and
I Brick (eds), Ten years of propranolol: a symposium
on the history and future of beta-blockade,
(Amsterdam, 26–28 Sept. 1975): 11–13, on p. 11.
6C Kennedy, ICI: the company that changed our
lives, London, Hutchinson, 1986, pp. 136–41.
Table 1
ICI’s Beta-Blockers
 1963: launch of Alderlin (compound 38,174, or pronethalol)
 1965: launch of Inderal (compound 45,520, or propranolol)
 1970: launch of Eraldin (compound 50,172, or practolol)
 1976: launch of Tenormin (compound 66,082, or atenolol)
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Viviane Quirkefor presentation of progress and results to ICI’s research managers, for the period before
Black’s arrival, during his presence at Alderley Park, and after his departure for Smith,
Kline & French’s UK laboratory in Welwyn Garden City.
When Black arrived at Alderley Park in 1958, a cardiovascular research programme had
begun to take shape there, and Black’s original approach to the problem of angina pectoris
benefited from the company’s growing experience with cardiovascular drugs.
7 Thus,
I begin with a brief history of ICI’s Pharmaceutical Division and the origins of its
cardiovascular programme.
ICI’s Cardiovascular Research Programme before Black (1954–1958)
ICI had been created in 1926 from the merger between the four largest companies in the
British chemical industry: Brunner, Mond & Co. Ltd, Nobel Industries Ltd, the United
Alkali Co. Ltd, and the British Dyestuffs Corporation Ltd.
8 It was within the Dyestuffs
Group (renamed Division in 1944) laboratories at Blackley, north of Manchester, that ICI
first began to carry out pharmaceutical research. This happened in 1936, after Gerhard
Domagk, whose work in the laboratories of the German firm Bayer was modelled on Paul
Ehrlich’s research on the therapeutic uses of dyestuffs, had found that the red dye Prontosil
possessed antibacterial activity.
9 At the Pasteur Institute in Paris, Ernest Fourneau and his
team discovered that the active part of the molecule was the colourless substance sulpha-
nilamide, which had long been known and therefore could not be covered by patents.
10
This discovery prompted the decision to set up a Medicinal Chemicals Section within
the Dyestuffs Group of ICI, a decision that was encouraged by the company’s academic
advisors, who included Carl Browning (Professor of Bacteriology at Glasgow
University).
11 At first compounds were sent for testing to researchers in medical school




As soon as the war broke out, ICI moved into the production of synthetic drugs formerly
imported from Germany, particularly the anti-malarials Mepacrine and Pamaquin, equiva-
lent to ‘‘Atebrine’’ and ‘‘Plasmochin’’.
13 They also became involved in the production of
penicillin, developing the first industrial process for manufacturing the drug by surface
culture.
14 In 1942, the group became key partners in two crucial wartime Anglo-American
7ForamoredetailedanalysisoftheoriginsofICI’s
cardiovascular research programme, see V Quirke,
‘From evidence to market: Alfred Spinks’ 1953 survey
of new fields for pharmacological research, and the
origins of ICI’s cardiovascular programme’, in
VBerridgeandKLoughlin(eds),Medicine,themarket,
and the mass media: producing health in the twentieth
century, London, Routledge, 2005, pp. 144–69.
8W J Reader, Imperial Chemical Industries: a
history, 2 vols, London, Oxford University Press,
1975, vol. 2, pp. 3, 13.
9See J Lesch, ‘Chemistry and biomedicine in an
industrial setting: the invention of the sulfa drugs’,
in S H Mauskopf (ed.), Chemical sciences in the
modern world, Philadelphia, University of
Pennsylvania Press, 1993, pp. 158–215.
10D Bovet, Une Chimie qui gue ´rit: histoire de la
de ´couverte des sulfamides, Paris, Payot, 1988.
11Kennedy, op. cit., note 6 above, pp. 120–1.
12K Holland, ‘IC Pharmaceuticals’,
Pharmaceutical Journal, Sept. 1987, 12: 286–8. See
also C W Suckling and B W Langley, ‘Francis Leslie
Rose, 1909–1988’, Bio. Mem. F.R.S., 1990, 36:
491–524, on p. 498.
13Reader, op. cit., note 8 above, vol. 2, p. 286.
14Ibid.
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James Black, Receptor Theory and the Development of Beta-Blockers at ICIpharmaceutical researchprogrammes:the firsttodevelopnovelsynthetic anti-malarials,in
a project that culminated in the discovery of ICI’s Paludrine and Winthrop’s Chloroquine,
and the second to produce penicillin on a large scale and find a synthetic route to its
manufacture.
15 In 1942, the profits made from sulphonamide and anti-malarial drugs led to
the creation of a selling company devoted to pharmaceuticals, IC (Pharmaceuticals) Ltd,
and the founding of a veterinary business.
16 In 1944, recognizing the growing importance
of pharmaceuticals within Dyestuffs, ICI’s main board formed a separate Pharmaceutical
Division.
17
The experience gained in synthesizing, testing and manufacturing anti-malarials was to
have a considerable impact on ICI’s pharmaceutical R&D after the war. Not only did it
provide the company, for a time at least, with profits to invest back into pharmaceutical
research, but it also provided ICI’s scientists with chemical leads for synthesizing new
drugs. In particular, clinical observations of the hypotensive side-effects of certain anti-
malarials provided leads for novel anti-hypertensive agents.
18 However, at ICI this only
happened once hypertension had been adopted as a research topic.
ICI’s cardiovascular programme developed gradually after the acknowledgement in
1948, at the second meeting of the Pharmaceutical Division’s newly-formed Chemother-
apeutic Research Committee, that of all chronic afflictions hypertension was the most
serious.
19 Because of the potentially large numbers of patients involved, estimated by the
Committee at 90 per cent of the population over the age of fifty in so-called ‘‘civilized’’
countries,
20 it was therefore considered worthy of the company’s attention. However,
because its cause was uncertain, and it was difficult to reproduce in the laboratory, it
was also recognized as requiring a ‘‘speculative’’ approach, that is to say a theoretical
approach to drug development, based on scientific hypotheses, in contrast with more
routine chemical investigations.
21
In 1951, hypertension was put forward as a new research target,
22 but it did not become
an actual research topic, within a wider programme to study diseases of ‘‘organic dysfunc-
tion’’,
23 until 1954, when a new pharmacological section was established at Blackley. As
well as hypertension, this section included the study of diuretics, anticoagulants, local
anaesthetics, pancreatic function, inflammatory conditions, and gastric secretion. James
Raventos,abiologistwhohadjoined ICI’spharmaceutical laboratoriesin1938,workedon
the last topic.
24 Alfred Spinks, an ICI chemist, who in 1950 had been sent to Oxford
15Kennedy, op. cit., note 6 above, pp. 127–9.
16Holland, op. cit., note 12 above, vol. 2, p. 286.
17Reader, op. cit., note 8 above, vol. 2, p. 459;
Kennedy, op. cit., note 6 above, p. 129.
18J A Woodbridge, ‘Social aspects of
pharmaceutical innovation: heart disease’, PhD thesis,
University of Aston, Birmingham, 1981, p. 26.
19AstraZeneca ICI research report (hereafter ICI)
CPR 3: minutes of 2nd meeting of the
Chemotherapeutic Research Committee, 31 March
1948. ICI records are held at Alderley Park, Cheshire.
20Ibid., minutes of meeting, 24 Sept. 1951.
21Ibid., minutes of 1st meeting, 19 Jan. 1948.
A member of the committee, Dr J Madinaveitia, for
example, drew the Committee’s attention to the
‘‘importance of biochemical work as a basis for
new ideas and new lines of synthetic work’’.
However, pharmacology rather than biochemistry
was to provide ICI with their first angle of
approach to the problem of hypertension.
22Ibid., minutes of meeting, 19 July 1951.
23The term ‘‘diseases of organic dysfunction’’,
rather than the now more familiar ‘‘chronic diseases’’,
was used at ICI to distinguish their study from that of
infectiousdiseases.ICICPR33:ResearchDepartment,
Biological Group (Diseases of Organic Dysfunction)
Report, Oct.–Dec. 1954.
24ICI CPR 3: 31 March 1953; ICI CPR 8: 1 Dec.
1954; ICI CPR 11: joint plan for 1954. On Raventos,
see D G Davey, ‘Dr James Raventos’, obituary,
Br. J. Pharmacol., 1983, 80:3 .
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Viviane QuirkeUniversity to acquire training in the biological sciences, and on his return to
Blackley designed and led the pharmacological section, took the largest share of the
programme.
25 Assisted by the chemist E H P Young and the technicians Brian Horsfall
and D Dunlop, he worked on hypertension, diuretics, anticoagulants, local anaesthetics,
and sedatives. In 1955, the section was augmented by a new unit, on atherosclerosis, led
by the biochemist J M Thorp, who went on to discover the hypolipidemic actions of
clofibrate.
26
When ICI’snew pharmaceutical researchcentre,AlderleyPark,opened in1957,ICIhad
therefore been working on topics related to heart disease for three years. Spinks’ research
on hypertension led to the ganglion-blocker pempidine, launched in 1958 under the name
Tenormal.
27 These drugs, which were quaternary ammonium derivatives, were widely
used for the treatment of hypertension in the UK in the 1950s. However, they were poorly
absorbed orally and caused side-effects, including postural hypotension and constipation.
Consequently, when Black arrived at Alderley Park in 1958, ICI were preparing to alter
their approach to the problem of hypertension, and start looking at central, rather
than peripherally-acting agents.
28 By 1959, the title of the series of research reports on
‘‘Anaemia, allergy, rheumatism, and cardio-vascular diseases’’ reveals that a proper
cardiovascular programme was in place at ICI.
29
Not only did Black find in ICI an organization with an interest and expertise in heart
disease, but Ahlquist’s dual receptor theory, which he would apply there in order to
devise a new way of treating angina pectoris, was beginning to gain acceptance among
scientific circles. Here follows a short summary of the history of receptor theory before
Ahlquist.
Receptor Theory before Ahlquist (c. 1900–1948)
The roles of Ehrlich and Langley in the formulation of receptor theory at the end of the
nineteenth and beginning of the twentieth century has been examined in depth.
30 However,
according to the historian of pharmacology John Parascandola, it was largely through
A J Clark’s quantitative work on the interaction between drugs and receptors in cells in the
1920s and 1930s that the theory began to spread among pharmacologists.
31 Clark had
25A W Johnson, F L Rose and C W Suckling,
‘Alfred Spinks, 1917–1982’, Bio. Mem. F.R.S.,
1984, 30: 567–94.
26ICI CPR 35: Research Report of the Biological
Group (Pharmacological Section) for July-Dec. 1955.
J M Thorp, ‘An experimental approach to the problem
of disordered lipid metabolism’, J. Atheroscler.
Res., 1963, 3: 351–60.
27Johnson, et al., op. cit., note 25 above, p. 584.
28R Vos, Drugs looking for diseases: innovative
drugresearchandthedevelopmentofthebeta-blockers
and the calcium antagonists, Dordrecht, Kluwer
Academic, 1991, pp. 81–2. This comment is based
on an interview with Black.
29ICI CPR 50, 50/3: Research Department Period
Report, 22 Jan. 1959.
30Pr€ u ull, op. cit., note 1 above; also Maehle,
op. cit., note 1 above.
31Parascandola, ‘The development of receptor
theory’, op. cit., note 1 above, pp. 150–3; idem,
‘AJ Clark:quantitativepharmacologyand thereceptor
theory’, Trends Pharmacol. Sci., 1982, 3: 421–3.
On Clark, see also Pr€ u ull, et al., op. cit., note 2 above,
pp. 26–7. For an indirect view of the development and
gradual acceptance of receptor theory, see A Albert’s
seriesoftextbooksonSelectivetoxicity.Itisinteresting
to note that it was not until Albert became more
confidentinthescientificbasisofreceptortheory,inthe
3rdeditionoftheseriespublishedin1965,thathebegan
to appreciate the role played by Clark. A Albert,
Selective toxicity, 3rd ed., London, Methuen,
1965, pp. 45–7.
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James Black, Receptor Theory and the Development of Beta-Blockers at ICItrained in physiology at Cambridge University at the time when Langley was
elaborating his theory of receptive substances in 1903–7.
32 Clark’s interest in the subject
was sparked off by Walter Dixon, who taught pharmacology there. In 1919, Clark moved
to University College London, where he succeeded A R Cushny in the chair of pharma-
cology, and began work on the neurotransmitter acetylcholine. It was this research
which led him to receptor theory.
33 In 1926, Clark left for Edinburgh, where he occupied
the chair of materia medica after Cushny’s death. There he pursued his work on
acetylcholine, showing in experiments with Raventos (this was before he joined ICI’s
pharmaceutical laboratories at Blackley) that the antagonism between acetylcholine and




considerable impact on the discipline of pharmacology.
35 Using a mathematical approach
to analyse a large amount of pharmacological data, Clark showed that for many drugs the
relationshipbetweendrugconcentrationandbiologicaleffectcorrespondedtoahyperbolic
curve,similartothatrepresentingtheadsorptionofagasontoametalsurface.Fromthis,he
concluded that the curve expressed the equilibrium between a drug interacting with a
specific number of receptors on the cell, and that the pharmacological action produced by
the drug was ‘‘directly proportional to the number of receptors occupied’’.
36 By the time
Clark had developed his version of receptor theory, it fitted well with the 3-D picture of the
cell that was being developed at the time. This may explain why it was this version which,
in Parascandola’s view, helped to establish the drug receptor concept in pharmacology.
37
However, it was not until after the Second World War that it became an important focus
for pharmacological research, for example in the work of E J Ari€ e ens in Utrecht and
R P Stephenson in Edinburgh, who modified Clark’s occupancy theory to explain the
affinity (i.e. the attraction between a compound and a receptor) and the efficacy (i.e. the
ability of the drug-receptor complex to elicit a physiological response, or ‘‘intrinsic
activity’’) of drugs.
38 In addition, Stephenson introduced the concept of partial agonist,
to signify a compound with high affinity but low efficacy, thereby making an important
distinction between the affinity of a drug for a receptor, and its potency once attached, a
concept that later became important in beta-blockade.
39
At the same time as these theoretical developments were taking place, the institutional
basis of pharmacology within universities and drug companies was expanding. Moreover,
the fast increase in the numbers of structure-activity studies, made possible by technolo-
gicaldevelopmentsandnewinsightsintheoreticalchemistry,meantthatconceptualization
32On Clark’s life and scientific career, see
E V Verney and I Barcroft, ‘Alfred Joseph Clark,
1885–1941’, Obit. Not. F.R.S, 1939–41, 3: 969–84.
33Parascandola, ‘The development of receptor
theory’, op. cit., note 1 above, pp. 149–50.
34A J Clark and J Raventos, ‘The antagonism of
acetylcholine and of quaternary ammonium salts’,
Q.J.Exp.Phys.,1937,26:375–92.SeealsoVerneyand
Barcroft, op. cit., note 32 above, p. 974.
35Parascandola, ‘A J Clark’, op. cit., note 31
above, p. 422.
36Clark is quoted in Pr€ u ull, et al., op. cit.,
note 2 above, p. 27.
37Parascandola, ‘The development of receptor
theory’,op.cit.,note1above,p.151;idem,‘AJClark’,
op. cit., note 31 above, p. 422.
38E J Ari€ e ens, ‘Affinity and intrinsic activity in the
theory of competitive inhibition’, Arch. Int. Pharma.
The ´ra., 1954, 99: 32–49; R P Stephenson,
‘A modification of receptor theory’, Brit. J.
Pharmacol. Chemother., 1956, 11: 379–93.
39Woodbridge, op. cit., note 18 above, p. 137.
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Viviane Quirkeof the reactions between drugs and tissues in terms of receptors was gradually becoming
more acceptable, and more deeply ingrained in laboratory practice.
40
Thus, receptor theory emerged progressively from a variety of research fields, which
included immunology, chemical work on metabolism, a mathematical approach to phar-




the SNS on the one hand, and studies of the interactions between drug or hormone and cell
on the other.
42 The idea of drug-receptor interaction had been developed early on in
connection with the SNS by Langley, although he did not use the word ‘‘receptor’’,
introduced in 1900 by Ehrlich in the context of his immunological research, but rather
‘‘receptive substance’’.
43 Thus, he had arguedthat certain drugs,like the suprarenal extract
adrenaline, which produce an effect similar to electrical stimulation of the sympathetic
nerves, bound to receptive substances in cells and that there were two types of such
substances, ‘‘motor’’ (excitatory) and ‘‘inhibitory’’.
44 His results were soon confirmed
by Henry Dale, who showed that while the excitatory actions (i.e. vasoconstriction and
contraction of smooth muscle) of adrenaline and other structurally similar compounds in
most tissues were blocked by ergot alkaloids, their inhibitory effects (i.e. vasodilation and
relaxation of bronchial muscle in the lungs) were not.
45 However, Dale, who became a
hugely influential figure in British medicine generally, and pharmacology in particular,
46
like other researchers remained sceptical about Langley’s idea that drugs combined
with specific receptive substances or ‘‘side-chains’’, and subsequently failed to give his
full support to the concept of receptor.
47 Thus, it is through a later interaction between
research on the SNS and receptor theory that the concept of beta-blockade eventually
emerged.
48 This happened after the publication of Ahlquist’s seminal paper in 1948.
Ahlquist’s Dual Receptor Theory before the Beta-Blockers (1948–1960)
Ahlquist’s paper had begun as an investigation into the ability of sympathomimetic
amines (i.e. compounds like adrenaline that ‘‘mimic’’ stimulation of the SNS—a term
coined by George Barger and Dale in 1910
49) to reduce the tone of uterine muscle in order
to alleviate period pains. Having carried out a comparative study of a series of these
compounds, Ahlquist found that the responses to them in a variety of tissues existed in
40Ibid.,pp.127,135–6.SeealsoAAlbert,Selective
toxicity, 5th ed., London, Methuen, 1973, p. 220.
41Pr€ u ull, et al., op. cit., note 2 above, p. 27.
42Woodbridge, op. cit., note 18 above, p. 115.
43Maehle, op. cit., note 1 above, p. 173.
44J N Langley, ‘On the reaction of cells and of
nerve-endings to certain poisons, chiefly as regards the
reaction of striated muscle to nicotine and to curari’,
J. Physiol., 1905, 33: 374–413.
45H H Dale, ‘On some physiological actions of
ergot’, J. Physiol., 1906, 34: 163–206.
46See W F Bynum, An early history of the British
Pharmacological Society, 1931–1981, London,British
Pharmacological Society, 1981, pp. 8–9. By the
time of the Second World War, Dale’s leadership
in science administration meant that he was
himself no longer closely involved in scientific
research.
47Maehle, op. cit., note 1 above, p. 171. See
also a later article by Dale on ‘Pharmacology and
nerve-endings’, Proc. R. S. Med., 1935, 28: 319–32,
on p. 319.
48Woodbridge, op. cit., note 18 above, p. 115.
49G Barger and H H Dale, ‘Chemical structure and
sympathomimetic action of amines’, J. Physiol.,
1910–1911, 41: 19–59.
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James Black, Receptor Theory and the Development of Beta-Blockers at ICItwo orders of potency. These results led him to question whether adrenergic receptors (the
receptors at which the neurotransmitter passes on messages from sympathetic nerves)
could be classified simply as either excitatory or inhibitory, and to conclude that there
existed two distinct types of adrenergic receptors, which he named alpha and beta.
50 Thus,
stimulationofalpha-receptorsresultedinexcitatoryresponsessuchasvasoconstrictionand
contraction of smooth muscle in a variety of tissues, whereas stimulation of beta-receptors
led to inhibitory responses such as vasodilation, and bronchial and uterine muscle relaxa-
tion. However, Ahlquist had also observed in the case of the heart, which he studied as an
isolated part of the cardiovascular system, that excitatory responses such as the increase in
rateandforceofcontraction correspondedtothebeta-receptorsandnotthe alpha-receptors
as in other tissues.
51
Ahlquist’s findings helped to explain the anomalous pharmacological properties of
isoprenaline (a b-agonist), which did not provoke vasoconstriction, pressor response (a
rise in blood pressure), or cause decongestion, as might have been expected of a sym-
pathomimetic amine, but on the contrary produced vasodilation, depressor response and
tachycardia, a fact that had long puzzled pharmacologists. Furthermore, his results went
some way to clarify the actions of the known sympatholytics (i.e. compounds that oppose
the effects of stimulation of the SNS) as ‘‘a-blocking agents’’.
52 In time, Ahlquist’s dual
receptor theory became a paradigm for the experimental study of adrenergic receptors and
the development of adrenergic drugs, and provided a model for the pharmacological and
physiological study of the SNS.
53
However, according to Black, this was a paper before its time.
54 It was rejected for
publication by the Journal of Pharmacology and Experimental Therapeutics because of
objections made against its methodology, and because its central tenet, that adrenaline was
the principal neurotransmitter, had been disproved in 1946 by Ulf S von Euler who had
shown that it was, in fact, noradrenaline.
55 It was published finally in 1948 thanks to
Ahlquist’s friend and colleague W F Hamilton, editor of the American Journal of
Physiology. Nevertheless, it was largely ignored for about ten years, until 1958, the
year in which Black began his work at Alderley Park. Black has explained this ten
year gap by arguing that Ahlquist’s paper had remained hidden ‘‘in the long shadows
cast by two giants—H.H. Dale in England, and W.B. Cannon in the USA’’. Dale, in
particular, although he came close to thinking in terms of receptors, ‘‘never gave receptor
theory the benefit of his huge scientific support’’, and consequently his attitude ‘‘seems to
have had a powerful effect in delaying the introduction of the idea of receptors into
pharmacological teaching and his impact was still dominant when Ahlquist’s paper
appeared in 1948’’.
56
50R P Ahlquist, ‘A study of the adrenotropic
receptors’, Am. J. Phys., 1948, 153: 586–600;
Idem, ‘Adrenergic receptors: a personal and
practical view’, Perspect. Biol. Med., 1973,
17: 119–22.
51Vos, op. cit., note 28 above, pp. 71–2.
52Ahlquist, ‘Adrenergic receptors’, op. cit.,
note 50 above, p. 120.
53Vos, op. cit., note 28 above, pp. 72, 76.
54Kennedy, op. cit., note 6 above, p. 137.
55Vos, op. cit., note 28 above, p. 75. Also
G O Carrier, ‘Evolutionof the dualadrenergic receptor
concept: key to past mysteries and modern therapy’, in
Parnham and Bruinvels (eds), op. cit., note 1 above,
pp. 203–21, on pp. 217–18.
56See Black, op. cit., note 5 above, p. 12.
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Viviane QuirkeCannon’s influence, on the other hand, had imprinted the minds of generations of
biologists with images of a system beautifully adapted to survival. In his theories there
was little room for the idea that the activity of the sympathetic nervous system might not
always have survival value. To account for its deleterious effects, Cannon came up with a
theory(described by Black as‘‘a baroque theory’’
57) of two sympathins Eand I, which was
the accepted doctrine at the time of Ahlquist’s paper. Although von Euler’s research
had already begun to erode the factual basis of Cannon’s sympathin theory and, in
1949, A M Lands commented in the first volume of the journal Pharmacological Reviews
thattheconceptofsympathinsEandIasmediatorsofadrenergicnerveimpulsesseemedto
have outlived its usefulness, it remained none the less widely accepted as a conceptual
framework, which delayed the acceptance of Ahlquist’s dual receptor theory.
58
Then, in 1958, came C E Powell and I H Slater’s description of the pharmacological
properties of Eli Lilly’s new compound dichloroisoproterenol (DCI), which according to
Black ‘‘provided the turning point and [led to] the rapid acceptance of the idea of a dual
receptor mechanism’’.
59 DCI was an analogue of isoprenaline,whichhad been synthesized
by the Eli Lilly group with a view to exploiting isoprenaline’s bronchodilator properties,
but which intrigued them by antagonizing its effects on the heart. However, although they
described DCI’s properties in terms of Ari€ e ens’ and Stephenson’s concepts of affinity and
intrinsic activity, Powell and Slater did not refer to Ahlquist’s work in their article.
60
Published by the Journal of Pharmacology and Experimental Therapeutics (ironically
perhaps, after the editorial board’s rejection of Ahlquist’s 1948 paper), it was followed six
months later by another by N Moran and M E Perkins in the same journal, in which they
argued that DCI’s activity belonged to Ahlquist’s ‘‘beta-adrenergic’’ type, and coined the
term ‘‘beta-adrenergic blocking drug’’, later shortened to ‘‘beta-blocker’’.
61
In his book Drugs looking for diseases, Rein Vos has argued that Moran and Perkins’
recognition of DCI as the exemplar of a new class of bio-active compound (the first beta-
blocker in fact) did not occur by chance, but rather that it was the result of a complex
process of disciplinary transformation which affected both pharmacologists and clinical
scientists.
62 However, as Desmond Fitzgerald has shown, there was an important element
of chance in this, for Moran had been studying the cardiovascular effects of different
catecholamines (substances which act mainly as neurotransmitters on the sympathetic and
central nervous systems) when he happened to hear Powell and Slater’s paper.
63 Chance
57Ibid.
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James Black, Receptor Theory and the Development of Beta-Blockers at ICIalso played a part in the next step, which led Black to pronethalol and then propranolol, for
hehadonlyjustjoinedICI’scardiovascularteamwhenhereadMoran’sreportandrealized
that it would be possible to synthesize an analogue of DCI.
64 He hoped that this analogue,
unlike DCI, which showed a degree of stimulant activity and turned out to be a partial
agonist, would be clinically useful.
65
Therefore, if DCI is to be considered as the ‘‘departure compound’’, which eventually
led to propranolol,
66 then the finding that DCI selectively blocked beta-receptors
has proved to be ‘‘one of the most significant advances in human pharmacotherapy’’.
67
It was Moran and Perkins who accomplished this, and in the words of the clinicians,
J M Cruickshank and B N C Prichard, ‘‘the major contribution of Black was to appreciate
the possible clinical value of developing compounds to inhibit the sympathetic nerves to
the heart, and then to persuade, and then lead a team of scientists at ICI to translate the idea
into reality’’.
68
As a physiologist with medical training, Black developed a clinical orientation a pure
scientist might not have had, and this was to play a key role in his ability to translate
Ahlquist’s dual receptor theory from an academic to an industrial setting.
69 Furthermore,
unlike pharmacologists working on the SNS, he was unhindered by classic beliefs and the
frustrating experiences in the field.
70 In the next section, I describe briefly the path which
took him from Glasgow University’s Veterinary School, where he developed his ideas
about beta-adrenergic receptor antagonists, to Alderley Park, where he realized them.
James Black, from Glasgow to Alderley Park (1950–1958)
Black studied medicine at St Andrews University in Scotland, where he graduated in
1946. He then joined the University’s Physiology Department under Professor R C Garry,
before accepting a lectureship atthe KingEdward VII College of Medicine in Singapore in
1947. On his return in 1950, a chance encounter in London with Garry led to him being
introduced to the Director of the University of Glasgow Veterinary School, William
Weipers, who offered him a post. In the School, Black built up a ‘‘state-of-the-art’’
physiological laboratory and encouraged colleagues to come and work with him, including
the academic surgeons Adam Smith and George Smith.
71 These collaborations would help
to shape Black’s future research programme. With Adam Smith, he began work on the
effects of5-hydroxytryptamine onhistamine inthe increase ingastric secretions, a topiche
64Kennedy, op. cit., note 6 above, p. 137.
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London, Edinburgh, Churchill Livingstone, 1994,
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72 With George Smith, a professor of surgery from Aberdeen who had become
familiar with American concepts and methods in cardiovascular physiology and surgery,
and whose main interest lay in finding ways of increasing the supply of oxygen to the heart
in patients with narrowed arteries, he also began work on the cardiovascular system.
73
Black had personal as well as professional reasons for his interest in cardiovascular
disease, more specifically angina pectoris. This is a painful illness, which occurs when the
demand for blood by the heart exceeds the supply of the coronary arteries, leading to an
increased heart rate and insufficient oxygenation of the heart. Black’s father had suffered
from it, and his death from a heart attack following a car crash had made Black ponder the
roleofstressinproducingadrenaline, anginaandheartattacks.
74Many ofthedrugsusedto
treat angina at the time were vasodilators, in particular nitrites, which increased the blood
supply, and therefore the amount of oxygen to the heart, but which caused flushing of the
face and headaches.
75 Some time in the mid-1950s,
76 Black ‘‘turned the problem on its
head’’,andhypothesizedthat,insteadoftreatinganginabyincreasingthesupplyofoxygen
to the heart, it might be possible to do so by reducing the demand from the heart.
77
Ahlquist’s paper, which he first came across in a 1954 edition of Drill’s Pharmacology,
78
provided him with a solution, suggesting that it should be possible to block the receptors
responsiblefortheincreasedheartrate.Thus,the‘‘Beta-blockerproject’’wasbornin1956,
when Black started searching for substances antagonizing the effects of adrenaline and
noradrenaline on the heart.
79
In the course of this search, Black found that the commercial extract of bovine heart
muscle Recosen, marketed by Robapharm in Switzerland for the treatment of angina,
80
protected rabbits against the vasoconstrictor effect of pitressin, but also observed that this
effect was exerted on the heart, not on the blood vessels.
81 Urged on by a friend who was
the local representative of ICI’s Pharmaceutical Division, Black turned to them in the hope
of obtaining a research grant.
82 ICI had long-standing relationships with a number of
Glasgow scientists, including Carl Browning, who retired in 1951, as well as with gastro-
enterologists and pharmacologists.
83 Moreover, since the creation of their veterinary
business in 1942, ICI had contacts with the Veterinary College and Hospital.
84 A visit
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James Black, Receptor Theory and the Development of Beta-Blockers at ICItoGlasgowwasthereforepromptlyarranged, andGarnet Davey, whowasabout tobecome
head of biological research at ICI, met Black. Learning of his project he offered him a
position, which Black, having heard ‘‘about this fairytale place ICI were building at
Alderley Park’’, accepted.
85 For this project, which was unusual and somewhat contro-
versial at the time, Black would benefit not only from Davey’s, but also from Spinks’
support.
86
Black, Receptor Theory, and DCI (1958–1960)
Thus, in 1958, Black began working on ICI’s coronary artery and hypertension projects,
taking over the biological aspects of two of the main cardiovascular areas under study at
Alderley Park. In his research, he was assisted by Brian Horsfall, a technician who had
worked with Spinks on hypertension (see above), and whom Black encouraged to set up an
instrumentation section in his laboratories.
87 The chemical side was left to ICI’s team of
organic chemists, which included J S Stephenson, who had recently joined ICI, and then
E H P Young, who like Horsfall had previously worked with Spinks on hypertension. For
the purpose of this paper, I will concentrate on coronary artery disease, within which the
beta-blocker project developed, and which soon overshadowed hypertension, until the two
projects finally separated in 1974.
Trawling through the literature,Black and Stephenson founda paper inComptesRendus
which claimed that it was possible to make adrenaline antagonists ‘‘par doublement de la
mole ´cule’’ (‘‘by doubling up the molecule’’).
88 Thus picking up where Ernest Fourneau
and Daniel Bovet had left off in the 1930s, they began searching for similar compounds.
89
However, this approach was put in question by the arrival of Powell and Slater’s, and
Moran and Perkin’s papers on DCI at the beginning of 1959.
Black realized the significance of DCI, especially it seems after Moran and Perkins had
described its action in terms of beta-receptors.
90 DCI, a sample of which had been synthe-
sized by Stephenson, was therefore tried in the Langerdorff preparation—the isolated,
spontaneously beating, guinea-pig heart. However, in this preparation, DCI showed sti-
mulant activities similar to those of isoprenaline. Hence, Black designed a new in vitro
85Kennedy, op. cit., note 6 above, pp. 136–7.
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Viviane Quirkeassay, the rate-controlled isolated papillary muscle test. On the strength of this test, which
made it possible to separate the effects of compounds on heart rate from those on force of
contraction, and in which DCI showed no stimulant activity, Black became convinced that
DCI was indeed the lead they had been looking for.
91
Black’sfirst research report, dated22January1959,represented acleardepartureforthe
cardiovascular research team. We contrast this with an earlier report by W S Waring in
1956 on the problem of atherosclerosis with Black’s in 1959. Waring had approached the
problem of atherosclerosis in terms of an indirect attack on cholesterol synthesis:
Working on the hypothesis that a high level of blood cholesterol is a predisposing factor in the
development of atherosclerosis and coronary thrombosis, attempts are being made to devise
compounds which will interfere with the biochemical mechanisms of cholesterol synthesis in the
body and thus reduce the level of cholesterol in the blood.
92
By contrast, Black analysed the same problem in terms of the underlying mechanism of
coronary artery disease: ‘‘One possibility, scarcely tested, is that altered fat metabolism
with associated changes in blood coagulability interact, permissively, with sympathetic
neurohumoural stress responses to produce fatal damage’’.
93
From his hypothesis on the role of SNS, he derived a direct therapeutic approach to what
he termed the ‘‘deleterious stress responses’’ leading to cardiovascular disease. The fol-
lowing paragraphs show Black linking his earlier work with bovine heart muscle extract,
DCI, and the beta-receptors of the heart, and deriving from the latter the means to imple-
ment his approach:
It has been shown ([by] J. W. B.) that a commercial extract of bovine heart muscle, given to rabbits
for a fortnight, protected the rabbit hearts against the coronary vasoconstrictor effects of pitressin.
Pharmacological testing of this extract showed the presence of anti-adrenalin activity with respect
to heart muscle but not with respect to blood vessels. A previous report from Sweden described an
unknown sympatholytic factor in cardiac muscle, ineffective against the pressor action of adrenalin
but active against the inhibitory effects of adrenalin in fowl caecum ...
There are two clearly differentiated sympathetic receptors—a receptors associated with
excitatory effects on blood vessels and smooth muscle and b receptors associated with inhibitory
effects on smooth muscle and possibly cardiac muscle. All the known adrenolytic agents are a
receptor inhibitors. Presumably the unknown factor in heart muscle is a b receptor inhibitor and
recently, the dichloro analogue of isoprenaline has been shown to be a powerful b receptor
inhibitor. The question of whether the latter compound will effectively block the cardiac
sympathetic responses remains to be satisfactorily answered.
It seems clear that the search for compounds which will block cardiac sympathetic responses
constitutes a clear-cut pharmacological problem and screening tests are being developed. In
addition, experiments are planned which will attempt to elucidate further the possible value of such
compounds in coronary artery disease.
94
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James Black, Receptor Theory and the Development of Beta-Blockers at ICIIn pursuit of his clear-cut pharmacological problem and therapeutic goal, Black devised
a series of screening tests on isolated tissue preparations and whole animals. After DCI had
been selected as their lead compound, the ICI team used a chemical structure-activity
approach in order to improve on DCI. In January 1960, reasoning that a second phenyl ring
might enhance the inhibitory activity of DCI, Stephenson replaced the two chlorine atoms
in DCI by another phenyl ring, to make a naphthalene.
95 This search for increased inhi-
bitory activity would remain a constant in the group’s subsequent work with the beta-
blockers.
From Pronethalol (Alderlin) to Propranolol (Inderal) (1960–1965)
The new compound synthesized by Stephenson in 1960 was 38,174 (pronethalol,
launched in 1963 under the name Alderlin after Alderley Park). It was found to be at
least asactive asDCI inthepapillary muscle test.Further testsshowedthat‘‘both drugs are
specific beta-receptor blockers, that DCI is slightly more sympathomimetic than 38,174,
that DCI is slightly less active than 38,174’’.
96 However, although he considered 38,174 to
be a highly promising lead, Black did not feel that the compound was ready as yet for
clinical trial. More work needed to be done on its toxicity before its suitability for trial
could be assessed.
In the meantime, in May 1960, a patent had been applied for, and Stephenson, who left
ICI around then, was replaced by A F Crowther, who directed the chemical work, while
R Howe and L H Smith completed the patent work as well as structure-activity studies, for
which a large number of analogues were synthesized.
97 The team grew from three in 1960
to thirteen by the end of 1963.Although most of the additional staff were chemists,early in
1962 ICI advertised for another cardiovascular specialist to work with Black. The person
they appointed had already had experience with beta-blocking compounds. He was
R G Shanks, who, after taking a BSc in physiology followed by a medical degree at
Belfast University, had spent a year with Ahlquist at the University of Georgia.
98 The
team working on the beta-blockers now comprised Black, Shanks, Horsfall, and Dunlop,
another ICI lab technician who had many years’ experience in cardiovascular disease.
99
A M Barrett, a pharmacologist who joined ICI’s beta-blocker project in 1964,
100 has
written that there are two reasons why synthesis of allied compounds continues even when
apreferredcompound—aswasthecasewithpronethalol—isdiscovered:‘‘(a)protectionof
the patent situation, and (b) protection of the market against the introduction of a better
compound by a competitor’’.
101 Between June 1961 and January 1962, 136 analogues
synthesized as part of the patent completion work were tested for structure-activity rela-
tionships, and Black searched among them for a compound that could improve on 38,174,
i.e. ‘‘(a) be longer acting; (b) have greater resistance to catecholamine ‘breakthrough’;
95Barrett, op. cit., note 60 above, p. 213.
96ICI CPR 50/6: 14 June 1960.
97Vos, op. cit., note 28 above, p. 85.
98Woodbridge, op. cit., note 18 above, p. 176.
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Viviane Quirke(c) show less penetration of the CNS’’.
102 However, by January 1962, no compound
superior to 38,174 had yet been found.
As small-scale trials had begun in 1961, a biochemistry section was added to the already
existingpharmacologyandchemistrysectionsofthecardiovascularprogramme.Newtests
were performed by W A M Duncan, using a spectrofluorometric method to estimate the
presence of pronethalol in blood and tissues.
103 Six months later, as part of the structure-
activity studies, Howe had discovered that in compounds which showed optical activity
(i.e. the ability to rotate the plane of polarization of a beam of polarized light passed
through a solution),the beta-blocking activity was confined tothe left-handed isomer only.
Although in itself not an unusual finding, Howe expressed it in terms of receptors, and, as
far as my evidence shows, this was the first time that structure-activity relationships were
described in this way at ICI:
The difference in biological activity between the members of a pair of racemes may be due to the
effect of a particular spatial arrangement at the b centre of asymmetry on the interaction with a
receptor, or to the effect ...of that centre of the interaction of the OH group or NH group with
a receptor, or combinations thereof.
104
This quote suggests that the concept of receptor had become a working tool for the ICI
researchers within the framework of the structure-activity studies of pronethalol.
By November 1962, 269 compounds, almost all of which were naphthalene, phenyl or
heterocyclic derivatives of pronethalol, had been tested. Black’s goal, of finding a superior
compound, still had not been achieved: ‘‘In these series ...we are dealing with a band-
spread of activity which will make it easier for competitors but difficult for us to find the
peak, the cr  e eme de la cr  e eme, of desirable properties’’.
105 On the other hand, in the process
of searching for such an ideal compound, a number of molecules with greater potency had
been discovered. In the naphthalene series, 45,520 showed ten to twenty times greater
activity than pronethalol. In addition, it showed a superior therapeutic ratio (an increased
ratio between blocking and toxic doses) in man. Compound 45,520 (propranolol, Inderal)
was, in fact, to become Alderlin’s replacement.
However, for the time being Black’s attention remained focused on pronethalol, and on
its mechanism of action. Now that it could be compared with a number of similar com-
pounds, its activity showed important implications for Ahlquist’s theory:
Although an injection of isoprenaline produces intense cardiac stimulation (and increases cardiac
output), the blood pressure falls because the compound also produces widespread dilation of blood
vessels. Both the cardiac and vascular effects of isoprenaline are conventionally classified as
b-receptor responses and it has been shown repeatedly that Alderlin can so completely block the
actions of isoprenaline that it no longer produces any cardiovascular responses. However, recently,
a number of compounds have been found which convert the usual depressor response of
isoprenaline to a marked pressor response. The action of one of these compounds has been
analysed. It was found that the compound was blocking the peripheral vasodilation of isoprenaline
but failing to block the cardiac responses. Thus the increased cardiac output delivered to undilated
vessels now produced a pressor response ...I think these results mean that one must be cautious
102ICI CPR 50/8: 21 Aug. 1961; ICI CPR 56/8:
26 Jan. 1962.
103ICI CPR 56/8: 26 Jan. 1962.
104ICI CPR 50/9: 7 Nov. 1962.
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James Black, Receptor Theory and the Development of Beta-Blockers at ICIabout turning Ahlquist’s dual receptor theory of adrenergic mechanisms into a sacred cow...
While there is no case for multiplying the number of postulated receptors (c.f. cholinergic
receptors) there is a case against a too-ready acceptance of dual receptor theory.
106 [My
emphasis.]
Thus, in the course of his experiments, Black had begun to modify Ahlquist’s dual
receptor theory into something more complex, involving a greater number of receptor
subdivisions. This suggested that it might be possible to develop compounds with even
more selective blocking activity than pronethalol. Black became fascinated with this idea
in relation to the treatment of peptic ulcers, with which he saw parallels with angina.
107 ICI
would explore the existence of further receptor subtypes later, in connection with the
cardio-selective properties of practolol (Eraldin) and atenolol (Tenormin), the next impor-
tant phase in their use of receptor theory as a tool for pharmaceutical innovation.
By April 1963, toxicity tests had shown that, whereas with pronethalol thymic tumours
appeared inmice within 120 days, with 45,520 no tumours had appeared since the tests had
begun in mid-December of the previous year. Nevertheless, Alderlin was launched in
November 1963, after the series of small-scale clinical trials had shown it to be effective in
angina and certain kinds of arrhythmias, although it was marketed primarily for conditions
that were life-threatening.
108 This rapid progress, from discovery (1960), to small-scale
trials (1961), and to marketing (1963), was not only due to a fairly relaxed regulatory
framework (this was before the 1962 thalidomide tragedy led to more stringent pre-launch
regulations), but also to the fact that experience with ganglion-blockers in the 1950s had
prepared the community of British cardiologists, with whom ICI developed close contacts,
for the arrival of the beta-blockers. Symptomatic of this, was the rapid rise in interest
amongst clinicians, with numbers increasing from four clinical centres investigating the
beta-blockers in 1961, to forty-five in 1965.
109
At this point, although he continued to work briefly on hypertension, Black began to
withdraw from the beta-blocker project, partly because of his lack of interest in the devel-
opment stage the project had now entered, and partly because, by analogy with the beta-
blockers,hewasbecomingcaptivatedbytheprospectofblockingthehistaminereceptorsin
the gut.





department, for a job so that he could work on histamine’s ‘‘b-receptors’’.
112
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Viviane QuirkeThe next section describes the development of beta-blockers after Black’s departure.
It shows how Black’s influence on ICI’s cardiovascular programme gradually faded, and
was replaced by other influences in response to the new challenge posed by competitors’
drugs. These provided a stimulus for investigations into further receptor subtypes, and
once receptor proteins had been isolated in the 1970s, for fundamental research into the
receptors themselves.
From Propranolol (Inderal) to Practolol (Eraldin) (1965–1970)
Shanks was now in charge of the pharmacological side of the beta-blocker and hyper-
tension projects, assisted by W Rouse, Duncan (who was later also recruited by Paget at
SK&F), and Dunlop.
113 The team sought a successor for Alderlin, and the different
properties of propranolol were compared with those of other Alderlin analogues.
Among these, the phenoxy analogue 45,763 was a clear favourite. However, it possessed
somedegreeofsympathetic stimulantactivity(PartialAgonistActivity—PAA,orintrinsic
sympathomimetic activity—ISA as it came to be known), which had been Black’s main
reason for dropping DCI in favour of pronethalol. Therefore the team, on whom Black’s
influence could still be felt, chose 45,520, i.e. propranolol.
114
A trade name for propranolol was needed, and the near-anagram of Alderlin, Inderal,
was selected. A new advisory body, the Committee on the Safety of Drugs (later re-named
theCommitteeonSafetyofMedicines(CSM))hadjustbeencreated,andalthough inthese
early days propranolol could have been marketed without a CSM submission, ICI’s
Medical Department decided ‘‘as an exercise’’ to prepare one.
115 For this, further toxicity
and distribution studies were carried out.
116
However, even before its launch, ICI was beginning to experience competition from
other companies. Mead Johnson had recently developed the beta-receptor antagonist
sotalol. Although less active than Inderal, it was also less toxic. Being very water soluble,
it showed less penetration of the central nervous system (CNS) (which led to side-effects
suchasnightmaresandhallucinations)andhadagreatertherapeuticratio.
117Thispotential
threat to Inderal led to the synthesis of further analogues, including 50,172 (practolol,
Eraldin) which was to succeed, although never replace, Inderal—as well as further inves-
tigations of its properties. It is interesting to note that, as part of these studies, Inderal was
tested for effects on histamine-induced gastric secretion rates by Dunlop.
118
Clinical trials started in summer 1964, and a year later Inderal was launched, only two-
and-a-half years after it had first been tested.
119 The ground for Inderal had been well
preparedbyAlderlin.Clinicianstookupstudyofthedrug,andshowedittobeeffectivenot
only in angina and arrhythmias, but later also in hypertension. Although it received little
113ICI CPR 56, 56/12: 24 Apr. 1964.
114Woodbridge, op. cit., note 18 above, pp. 191–3.
OnBlack’senduringinfluence,seeVos,op.cit.,note28
above, p. 89.
115Woodbridge, op. cit., note 18 above, p. 193.
116ICI CPR 99, 2B: Feb.–Apr. 1965 ; CPR 99 3B:
May–Aug. 1965.
117ICI CPR 56/12: 24 Apr. 1964 ; CPR 56/13:
13 Nov. 1964.
118ICI CPR 56/13: 13 Nov. 1964.
119Kennedy, op. cit., note 6 above, p. 138; Vos,
op. cit., note 28 above, p. 91.
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James Black, Receptor Theory and the Development of Beta-Blockers at ICIreaction at the time, the first paper on the use of propranolol as an antihypertensive drug by
Brian Prichard, a clinical pharmacologist who took part in the early trials in angina at
University College Hospital, has been seen retrospectively to have greatly influenced the
clinical development of beta-blockade.
120 There were some concerns about the safety of
propranolol, which had been shown to be involved in some cases of cardiac failure.
However, with enough positive evidence accumulating in its favour, ICI obtained clear-
ance from the CSM to market Inderal in hypertension in January 1969.
121 This event,
followed in 1973 by the US Food and Drug Administration’s (FDA) approval of Inderal as
an antihypertensive agent, helped to establish the beta-blockers in general, and Inderal in
particular in hypertension.
122
In addition, the broad patent coverage secured by Crowther and his colleagues for
propranolol consolidated ICI’s foothold in the beta-blocker field, and limited the freedom
of action of competitors to market compounds of their choice.
123 Perhaps because of this,
as well as the intrinsic merits of the drug, propranolol became the reference compound of
what may be called the ‘‘second generation of b-adrenoceptor inhibitors’’, which may
therefore be considered as ‘‘derivatives’’.
124
Nevertheless, in response to growing competitive activity,
125 and because Inderal had
been found to cause bronchoconstriction in patients with asthma, in 1966 ICI’s cardio-
vascular team turned to practolol, which had been shown not to block the bronchodilator
action of isoprenaline:
50,172 is the first compound of which we know that produces this selective blockade. The
importance of this finding is two-fold: it may be possible to obtain a compound (possibly 50,172)
which will not block the beta-receptors in bronchial muscle; consequently this compound could be
used in patients with reduced respiratory reserve not only for the treatment of angina, of cardiac
arrhythmias, but in combination with a catecholamine bronchodilator to prevent the side-effects of
cardiac stimulation.
126
ICI’s first priority, as it was defined by the pharmacologists, was the rapid choice of a non-
sympathomimetic selective blocker for clinical trial. On the chemical side, the most
important task was now‘‘to continue the beta-blocker work untilwe have made, evaluated,
selected and developed a preferred compound having each optimal activity pattern that we
can postulate. We must energetically use our shrinking scientific lead to maintain our
commercial lead’’ (my emphasis).
127 One of the means of achieving this was to pool the
scientific and technical capabilities available throughout ICI.
Thus, for the purpose of presenting structure-activity relations ‘‘on a more rational basis
than hitherto’’, R H Davies of Management Services was asked to prepare a computer
120B N C Prichard and P M S Gillam, ‘Use of
propranolol in the treatment of hypertension’, Br. med.
J., 1964, ii: 725; Woodbridge, op. cit., note 18 above,
p. 197. See also L Hansson, ‘The use of propranolol
in hypertension: a review’, in Hoffbrand, et al.,
op. cit., note 5 above, pp. 77–80.
121Woodbridge,op.cit.,note18above,pp.212–13.
122Ibid., p. 228.
123According to Barrett, this is actually an
impediment to therapeutic progress. Barrett,
op. cit., note 60 above, pp. 217, 226.
124Ibid., p. 217.
125Not onlywasthereMead Johnson’ssotalol,A B
H€ a assle’s alprenolol, but also Ciba’s oxprenolol, which
were all launched around the same time. Woodbridge,
op. cit., note 18 above, pp. 198–203, 214.
126ICI CPR 99, 5B: 25 May 1966.
127ICI CPR 99, 9B: 6 Nov. 1967.
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Viviane Quirkeprogramme based on information theory analysis,
128 and assist the cardiovascular team in
developing a reliable method of estimating cardiac beta-blockade and its effects on bron-
chial beta-receptors. Davies generated data on approximately 200 analogues of practolol,
fromwhichheexpectedtobeabletolocatethe‘‘receptorsites’’,forifrateofaccessproved
to be the dominant factor in selectivity then ‘‘the inferences on receptor sites...were
obvious’’.
129
Meanwhile, the pharmacologists pressed for practolol to be taken through to clinical
study, which ICI’s management, fearing renewed competition against Inderal, agreed to
do.
130 Shanks had left ICI in 1966, hence the development and marketing of practolol
became A M Barrett’s responsibility, with Desmond Fitzgerald, a clinical pharmacologist
who joined ICI in 1967, helping to set up the clinical trials.
131 Practolol was launched in
1970 under the name Eraldin.
Eraldin sold well, for the market for beta-blockers was now well established. However,
by 1974, it had been found to cause blindness in some patients, and ICI’s then medical
director, CC Downie, recommended its withdrawal ifskin rashes and associated shrinkage
of the conjunctiva appeared. A year later the CSM advised doctors about the dangers of
practolol, which led to a sharp drop in prescribing. ICI set up a compensation scheme, for
which the claims were to outnumber those for thalidomide by about 5 to 1, even though in
the end ICI did not pay out as much as they had originally budgeted for, as the exact cause
of the adverse symptoms were sometimes difficult to ascertain.
132 Nevertheless, these
events precipitated the choice of a successor for Eraldin among the compounds that were
then being subjected to a fundamental study of beta-blockade and beta-receptors.
Atenolol (Tenormin), b1 and b2 Receptors, and Rational Drug Design (1970–1978)
By1975,whenthe decision was takento withdraw Eraldinfrom the market, a number of
candidatemolecules,which were thoughtofas‘‘insurance’’over Eraldin, hadalready been
identified.
133
They included 66,082 and 61,081. Both compounds seemed close enough to the ‘‘ideal
beta-blocker’’ sought by the cardiovascular team.
134 66,082 (atenolol, Tenormin), unlike
propranolol, had no membrane-stabilizing action, which, it was thought at the time, might
be linked to cardiac failure.
135 Furthermore, unlike propranolol, it was water- rather than
lipid-soluble, therefore it was expected to show less penetration of the CNS. In all these
respects, compound 66,082 therefore appeared to be a ‘‘clean beta-blocker’’.
136 However,
whether selectivity was or was not a desirable property in a new beta-blocker reaching the
market in the 1970s remained to be proved, therefore it was not clear which of 66,082 or
61,081 was preferable (see Table 2).
128On the role of computers and information
science in drug design, see P J Lewi, ‘Computer
technology in drug design’, in E J Ari€ e ens (ed.), Drug
Design, New York, Academic Press, 1976, vol. 7,
pp. 209–75.
129ICI CPR 99, 13B: 27 March 1969.
130Woodbridge,op.cit.,note18above,pp.219–20.
131Fitzgerald joined ICI in 1967. See ICI CPR 99,
9B: 6 Nov. 1967.
132Woodbridge, op. cit., note 18 above, pp. 232–5.
133ICI CPR 99, 14B: 8 July 1969.
134ICI CPR 99, 13B: 27 March 1969.
135Membrane-stabilizing activity was later shown
to be unimportant in beta-blockade. See Cruickshank
and Prichard, op. cit., note 68 above, p. 7.
136Woodbridge, op. cit., note 18 above,
pp. 254–5.
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James Black, Receptor Theory and the Development of Beta-Blockers at ICIThe recent restrictions brought about by the Medicines Act of 1968 concerning human
use had made pre-clinical testing even more necessary than previously.
137 For this reason,
and to assist in the selection of the compound to succeed Eraldin, the potencies of the
different drugs were compared. Greater potency (corresponding to a lower ED50, see
Table 2) was now being described in terms of a ‘‘better receptor fit’’.
138 In addition,
quantitative and biochemical methods were adopted and modified to establish
structure-activity relations, and to ascertain—at an ever increasing level of detail—the
various properties of the compounds under study.
In 1969, the publication of an article in Nature describing Allen & Hanburys specific
beta-receptor stimulant AH 3365 (salbutamol, Ventolin) prompted the team to renew their
focus on selectivity.
139 Thus, the biochemist A R Somerville, working with H Tucker and
J Coope of the Pharmaceutical Division’s Chemistry Department, adapted the method
developed by Robert Lefkowitz in Durham using affinity chromatography,
140 in an effort
to isolate the recently discovered beta-receptor protein.
141 This, they hoped, would help
them to ‘‘understand more fully the finer details of beta-receptor antagonism’’, including
the nature of the beta-receptor itself, for the purpose of locating selective beta-blocker
action.
142
Meanwhile, Davies’ quantitative studies were nearing completion.
143 They suggested
that selectivity existed on account of slight changes in concentration attributable to phase
137Ibid., pp. 258.
138ICI CPR 99, 14B: 8 July 1969.
139ICI CPR 99, 14B: 8 July 1969. On the history of
Ventolin, see E Jones, The business of medicine,
London, Profile Books, 2001, pp. 330–3.
140A technique by which fixed ligands bind the
receptors in a solution, preventing their flow through a
chromatography column, with the effect of separating
them from other materials. See J D Robinson,
Mechanisms of synaptic transmission: bridging the
gaps (1890–1990), Oxford University Press, 2001,
p. 159.
141On the isolation of receptor protein from
cell membranes, see ibid., pp. 157–63. Somerville
found Lefkowitz’s method difficult to reproduce,
however.
142ICI CPR 99, 25B: 27 Feb. 1973.
143On the importance of quantitative-activity
studies in the rise of a rational approachto drug design,
see for instance Y C Martin, Quantitative drug design:
a critical introduction, New York, Marcel Dekker,
1978.
Table 2












Inderal 62 No Yes Yes No
Eraldin 167 Yes No No Yes
Aptin 80 No Yes Yes Yes
60,847 6 Yes No No Yes
66,082 96 Yes No No No
65,674 25 Yes Yes Yes Yes
61,081 112 No No Yes No
a Effective dose for 50 per cent of the tests carried out. A lower number indicates a more potent
compound.
Source: ICI CPR 99, 14B: 8 July 1969.
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Viviane Quirkedifferences immediately surrounding the receptors.
144 These results were fed back into the
cardiovascular research programme, and the hypothesis that ‘‘selectivity might reside in
the micro-environment surrounding the receptor, rather than in the receptor itself’’ was
tested in a variety of isolated tissue preparations. Because potency, as well as cardio-
selectivity, was desirable, Davies was also asked to re-evaluate quantitatively earlier data,
which had previously been expressed only in qualitative terms.
145 He did so using steady-
state model equations based on an extension of the Hansch equations (which apply multi-
ple linear regression to quantitative structure-activity relations or QSAR),
146 considered to
be the first of two possible approaches to the ‘‘design’’ of the ideal beta-blocker sought by
the team (see (a) below). This ideal compound, it was now believed, might not only be a
potent cardio-selective beta-blocking drug, but also a partial agonist, and therefore possess
some degree of ISA after all.
147 The second (see (b) below) consisted in the more
traditional, empirical chemical method of drug development:
There are two possible approaches to obtaining the ‘‘ideal beta-blocker’’:
(a) using the Hansch-type analysis ...to find compounds of increasing potency in existing series
(ureas and phenylhydrazones);
(b) extrapolating from current series into completely novel types.
148
In the event, both methods were used, and the chemists set out to synthesize molecules
which, on the basis of the hypothetical binding sites on the receptor, could adopt the
requisiteatomicspatialarrangementsforbindingtoreceptors.
149Weretheytoachievethis,
it was anticipated that it would then be possible to compute an approximation for the
optimum configuration for beta-receptor binding.
150
Thus, within the context of ICI’s beta-blocker programme, receptors were being trans-
formed from hypothetical entities into tangible objects, which could be apprehended using
a variety of scientific instruments, quantitative and biochemical methods, and be used to
predict the properties of novel compounds and for drug design.
151 The biochemical studies
of the beta-receptor,in particular, gave substance to the idea of beta-receptor subtypes, and
it was concluded ‘‘that there was a real difference in biochemical terms between b1 and b2
receptors’’.
152
144ICI CPR 99, 23B : 16 June 1972.
145ICI CPR 99, 22B: 7 March 1972.
146On Hansch’s method see Martin, op. cit, note
143 above, and also A Verloop, ‘The use of linear free
energy parameters and other experimental constants in
structure-activity studies’, in Ari€ e ens (ed.), op. cit., note
60 above, pp. 133–88.
147ICI CPR 99, 23B: 16 June 1972. Unlike
Black, H€ a assle’s researchers believed that
moderate beta-receptor stimulant action was useful
in a beta-blocker, therefore it is likely that this
change of position on ICI’s part was a response
to competitors’ drugs coming onto the market.
See Fitzgerald, op. cit., note 63 above,
p. 174.
148ICI CPR 99, 23B: 16 June 1972.
149ICI CPR B 99, 30B: 23 Oct. 1974.
150ICI CPR B 99, 30B: 23 Oct. 1974.
151On this progress from hypothetical entity to
tangible object see E J Ari€ e ens, ‘Receptors: from fiction
to fact’, Trends Pharmacol. Sci. inaugural issue, 1979,
pp. 11–15; and R P Ahlquist, ‘Adrenoceptors’, in ibid.,
pp. 16–17.
152ICI CPR B 99, 33B: 20 Oct. 1975.
A M Lands had identified b1 and b2 receptors in 1967,
concluding that while the former was prominent
in cardiac stimulation, the latter played an important
role in bronchodilation. A M Lands, et al.,
‘Differentiation of receptor systems activated by
sympathomimetic amines’, 1967, Nature, 214:
597–8. See Robinson, op. cit., note 140 above,
p. 154. The first time b1 and b2 receptors were
mentioned in ICI’s research reports was in CPR 99,
27B: 22 Oct. 1973.
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James Black, Receptor Theory and the Development of Beta-Blockers at ICIFurthermore, the beta-blockers themselves were becoming tools for isolating and
characterizing the beta-receptor. Thus, ICI’s chemists prepared a beta-blocker with a
fluorescent probe attached for use as a tool in the investigation of the beta-receptor,
for ‘‘it seemed reasonable to choose a beta-blocker (rather than any other compound)
as a ligand in an attempt to isolate the beta-receptor protein’’.
153 In 1976, ICI’s cardio-
selective beta-blocker, atenolol, was compared with Allen and Hanburys’ salbutamol,
which acted selectively on the bronchial muscle, with a view not only to isolating and
characterizing the beta-receptor, but also to confirming that there existed a difference in
receptor type, and that phase distribution played a role in selectivity.
154
Meanwhile, the quantitative study of the structure-activity relations of several series of
beta-blockers had progressed, and it was now possible to plot ISA against a particular
structural feature: the bulk of the ortho-substituent in the aromatic ring. The linearity of the
plots suggested that they might be useful in the prediction of ISA in new molecules (which
was particularly important for the selection of cardiotonics, on which the group had been
working since 1964, in conjunction with the beta-blockers).
155 The biochemical study of
potencies and cardio-selectivity ratios of beta-blocking drugs, compared on isolated mem-
brane systems from cardiac and uterus tissues and on isolated atrial and tracheal muscle
preparations, enabled the researchers to articulate hypotheses concerning drug binding in
the region ofthe receptor.In order to test these hypotheses, techniques were established for





certainly a reaction to Black’s discovery of the first H2-receptor antagonist, cimetidine
(Tagamet), at SK&F.
157
The withdrawal of Eraldin precipitated the choice of atenolol as ICI’s next beta-blocker.
It was launched in 1976 under the name Tenormin, reminiscent of ICI’s ganglion-blocker
Tenormal, as it was being marketed primarily as an antihypertensive. It became one of the
best-selling heart drugs and, within ten years, Tenormin and its related products generated
sales worldwide of about £500 million. Nearly 40 per cent of sales were made in the USA,
30 per cent in Western Europe (including the UK), 14 per cent in Japan, and 16 per cent in
the rest of the world.
158
Conclusions
By 1987, 36 per cent of the total value of the world’s top twenty selling medicines was
accounted for by H2- and beta-blockers, and nearly 75 per cent of these sales were of
products invented and developed in the UK.
159 James Black played a crucial part in the
development not only of the beta-blockers at ICI, but also of the H2-receptor antagonists at
153ICI CPR B 99, 30B: 23 Oct. 1974.
154ICI CPR B 99, 34B: 26 Feb. 1976.
155ICI CPR 99, 1B: Nov.–Dec. 1964 to Jan. 1965.
156ICI CPR B 99, 35B: July 1976.
157SeeFinucane,op.cit.,note112above,ch.10.On
the history of cimetidine, see also Maxwell and
Eckhardt, op. cit., note 60 above, pp. 365–76; and
M Ennis and W Lorenz, ‘Histamine receptor
antagonists’, in Parnham and Bruinvels (eds), op. cit.,
note 60 above, pp. 623–45.
158Holland, op. cit., note 12 above, p. 288.
159Ibid., pp. 286–7.
90
Viviane QuirkeSK&F. In both instances, his research represented a point of departure for the two firms,
and this gave them prime-mover status in their respective fields, as well as providing a lead
for other companies to follow.
160
However, the continuities provided by the industrial context in which he worked under-
pinned Black’s research projects and, ultimately, their successful outcome. When Black
arrivedatAlderleyParkin1958,ICIhadabuddingcardiovascularprogramme,ateamwith
expertise in cardiovascular disease, and were preparing to alter their approach after the
launchoftheirganglion-blockerpempidine.ThisprovidedBlackwithafruitfulframework
for his research as well as colleagues with skills complementary to his own. Black himself
has acknowledged that his ‘‘odyssey of painfully learning about pharmacology’’ began in
1958, when he joined ICI, and owed much to his colleagues there:
My years at I.C.I., between 1958–1964, were some of the most exciting of my life. I was assigned a
brilliant chemist, John Stephenson. He taught me about modern deductive organic chemistry ...He
converted me to pharmacology. Indeed, my whole experience at I.C.I. was an educational tour de
force. I had to learn how to collaborate across disciplines, how to change gears when changing from
research to development, how to make industry work—in short, how to be both effective and
productive.
161
As well as Stephenson, Black mentioned Crowther, Duncan, and Prichard. In addition,
this paper has highlighted the role of laboratory technicians, who had a long-term experi-
ence of techniques and instruments in the cardiovascular field. Moreover, it has shown
how, in the process of developing the beta-blockers, ICI built up distinctive pharmaco-
logical and biochemical capabilities, which were transferred to SK&F when Paget became
their head of R&D in 1963, followed by Black and Duncan.
With these continuities provided by the industrial context, also came a rationale that is
usuallyconsideredtobeexternaltoscience.Whilstfocusingonreceptortheoryasatoolfor
pharmaceutical innovation, I have alluded to the role of patenting, competitive activity,
commercial strategy, and drug safety regulations in the history of the development of the
beta-blockers. These aspects deserve to be more fully developed than they can be here, for
while Black had helped to place ICI at the forefront of pharmaceutical innovation in the
cardiovascular field, the firm’s patenting, competitive and commercial strategies also
contributed to their leading position on the market.
However, such continuities do not account for all aspects of the history of receptor
theory and its applications. James Raventos, who had worked with Clark in Edinburgh in
the 1930s, and joined ICI in 1938, was working on gastric secretions when Black arrived at
Alderley Park. Had his chief interest not been the anaesthetic drug Fluothane, perhaps he
would have gone on to develop histamine antagonists.
162 Although more research needs to
be done on the history of ICI’s research programme into gastric secretions, the fact that
they did not develop an H2-blocker like Tagamet suggests that, without Black, ICI’s
innovative capability in the cardiovascular field was not easily transferable to other
therapeutic areas.
160On the parallels between the two projects, see
Finucane, op. cit., note 112 above, p. 50.
161Black, ‘Biography’, op. cit., note 69 above,
p. 415.
162Davey, op. cit., note 24 above.
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James Black, Receptor Theory and the Development of Beta-Blockers at ICIOne questionthereforeremains:had Black not gone toAlderley Park in1958, would ICI
still have developed beta-blockers? Because of their burgeoning cardiovascular pro-
gramme, and because they were considering altering their approach at the time of Black’s
arrival, the answer is probably yes. However, it is also likely that the first beta-blockers
would have been developed elsewhere, a couple of years later, in Sweden by A B H€ a assle,
who, unlike others—such as Eli Lilly who had stumbled on beta-blocking compounds but
failed to conceive of a use for them in the clinic—were looking for anti-arrhythmic drugs
with beta-blocking properties. Therefore, without Black, ICI would almost certainly have
been followers rather than leaders in the field.
In his article entitled ‘Invention in the industrial research laboratory: individual act or
collectiveprocess?’,thehistorianoftechnologyDavidHounshellhasarguedthatinvention
isat once individual and collective, and also at once discreetmoment or act and continuous
process.
163 The history of the development of the beta-blockers at ICI not only reinforces
this analysis, it enriches it by bringing in the respective roles of theory and practice in
pharmaceutical innovation.
ICI’s beta-blocker project was based on Ahlquist’s dual receptor theory, which James
Black translated from an academic to an industrial context when he came to work at ICI’s
research centre in Alderley Park. In ICI, Black found an organization with an interest and
expertise in cardiovascular diseases, which provided him with a fruitful framework for his
project to find compounds to block the beta-adrenoceptors of the heart, for the treatment of
angina pectoris. The drugs that were the outcome of this programme, from propranolol to
Tenormin, in turn helped to establish receptor theory among scientists and pharmaceutical
companies, and in time became tools for investigating the nature and properties of beta-
receptors. Following the beta-blockers, Ahlquist’s dual receptor theory was applied in
pulmonary medicine, obstetrics, endocrinology, gastroenterology and psychiatry. Hence,
the 1960s and 1970s, which followed Black’s research at ICI, have become known as ‘‘the
age of the receptor’’.
164
163D A Hounshell, ‘Invention in the
industrial research laboratory: individual act or
collective process?’, in R J Weber and
D N Perkins, Inventive minds: creativity in
technology, New York, Oxford UniversityPress, 1992,
pp. 273–90.
164See A W Cuthbert, ‘Men, molecules and
machines’, Trends Pharmacol. Sci. inaugural issue
(1979): 1–3, on p. 3.
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